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Introduction: Human Epidermal Growth Factor Receptor (ERBB4/HER4) belongs to the Epidermal Growth Factor
receptor/ERBB family of receptor tyrosine kinases. While ERBB1, ERBB2 and ERBB3 are often overexpressed or activated
in breast cancer, and are oncogenic, the role of ERBB4 in breast cancer is uncertain. Some studies suggest a tumor
suppressor role of ERBB4, while other reports suggest an oncogenic potential. Alternative splicing of ERBB4 yields four
major protein products, these spliced isoforms differ in the extracellular juxtamembrane domain (JM-a versus JM-b) and
cytoplasmic domain (CYT-1 versus CYT-2). Two of these isoforms, JM-a CYT-1 and JM-a CYT-2, are expressed in
the mammary gland. Failure to account for isoform-specific functions in previous studies may account for conflicting
reports on the role of ERBB4 in breast cancer.
Methods: We have produced mouse mammary tumour virus (MMTV) -ERBB4 transgenic mice to evaluate potential
developmental and carcinogenic changes associated with full length (FL) JM-a ERBB4 CYT-1 versus ERBB4 CYT-2.
Mammary tissue was isolated from transgenic mice and sibling controls at various developmental stages for
whole mount analysis, RNA extraction, and immunohistochemistry. To maintain maximal ERBB4 expression,
transgenic mice were bred continuously for a year after which mammary glands were isolated and analyzed.
Results: Overexpressing FL CYT-1 isoform resulted in suppression of mammary ductal morphogenesis which was
accompanied by decreased number of mammary terminal end buds (TEBs) and Ki-67 positive cells within TEBs,
while FL CYT-2 isoform had no effect on ductal growth in pubescent mice. The suppressive ductal phenotype in
CYT-1 mice disappeared after mid-pregnancy, and subsequent developmental stages showed no abnormality in
mammary gland morphology or function in CYT-1 or CYT-2 transgenic mice. However, sustained expression of FL
CYT-1 isoform resulted in formation of neoplastic mammary lesions, suggesting a potential oncogenic function
for this isoform.
Conclusions: Together, we present isoform-specific roles of ERBB4 during puberty and early pregnancy, and
reveal a novel oncogenic property of CYT-1 ERBB4. The results may be exploited to develop better therapeutic
strategies in breast cancer.* Correspondence: vikram.wali@yale.edu
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ERBB4/human epidermal growth factor receptor 4,
the fourth member of the epidermal growth factor re-
ceptor (EGFR) family, is predominantly expressed in the
heart, brain, kidney, salivary glands, and mammary
glands [1]. In contrast to EGFR and ErbB2, which are
expressed and activated in mouse mammary glands at
puberty, ErbB4 is mainly active during pregnancy and
lactation [2,3]. The critical role of ErbB4 expression in
pregnant and lactating mammary gland development
was established using loss-of-function strategies. ErbB4
signaling is necessary for terminal mammary differenti-
ation and for signal transducer and activator of tran-
scription 5 (Stat5) activation late in pregnancy and
during lactation [4], and homozygous loss of function
leads to defects in pregnancy and lactation [5]. Addition-
ally, ErbB4 and its ligand Nrg3 have been implicated in
mammary bud specification in mouse embryos [6]. We
have previously shown that Neuregulin 1 (NRG1), a lig-
and for ErbB4 and ErbB3, induces proliferation and dif-
ferentiation of mammary epithelium in prepubescent
mice, indicating the presence of functional ErbB4 or/and
ErbB3 at early developmental stages [7]. However, the
exact roles of ERBB4 in mammary gland development in
nulliparous mice are not fully understood.
ErbB4 is unique in the EGFR family in that it yields
multiple alternatively spliced mRNA isoforms, and the
protein products undergo regulated extracellular and
intramembrane proteolysis. The spliced isoforms differ
in the extracellular juxtamembrane domain (JM-a vs.
JM-b isoforms) and the cytoplasmic domain (CYT-1 vs.
CYT-2), and their relative expression varies with tissue
type. The JM-a and JM-b isoforms use alternate exons
that encode sequences just outside the transmembrane
domain, with the JM-a sequences including a tumor ne-
crosis factor alpha-converting enzyme metalloproteinase
cleavage site rendering JM-a but not JM-b isoforms,
susceptible to cleavage. Tumor necrosis factor alpha-
converting enzyme cleavage of the JM-a isoform releases
the extracellular domain, leaving membrane-associated
80 kDa (m80) truncated ERBB4. This undergoes a sec-
ondary presenilin/γ-secretase-dependent intramembrane
cleavage, releasing a constitutively kinase-active soluble
intracellular domain (ICD), s80, which translocates to
the nucleus and regulates transcription [8,9]. The JM-c
isoform lacking sequences from both exons and the JM-
d isoform with both exon-encoded sequences have also
been reported. Cytoplasmic isoforms CYT-1 and CYT-2
differ in that 16 amino acids present in CYT-1 are ab-
sent in CYT-2 as a result of exon skipping in the latter.
This 16 amino acid peptide includes consensus binding
sites for WW domains and for the SH2 domain of the
p85 subunit of phosphatidyl-inositol (3′)-kinase, and
hence CYT-1 can activate the phosphatidyl-inositol (3′)-kinase–Akt pathway [10]. The WW domain-containing
ubiquitin E3 ligase Aip4/Itch binds to the PPXY1056
Itch binding site present only in CYT-1, resulting in
higher ligand-induced ubiquitination of CYT-1 than that
of CYT-2 [11]. Normal mammary glands and breast can-
cers express cleavable JM-a isoforms, CYT-1 and CYT-2
but not JM-b.
ERBB4 is one of the top 127 significantly mutated
genes across 12 cancers [12]. Potential oncogenic muta-
tions in the protein tyrosine kinase domain and else-
where in ERBB4 have been reported for melanoma,
gastric carcinoma, colorectal carcinoma, nonsmall-cell
lung carcinoma, and breast carcinoma, but most have
not been functionally validated. ERBB4 mutations are in-
frequent in breast cancer, with a prevalence of approxi-
mately 1% [12], and ERBB4 gene amplification is rare
[13,14]. ERBB4, predominantly the CYT-1 isoform, is
overexpressed in medulloblastoma [15]. Correlative bio-
marker studies have implied either pro-tumorigenic or
anti-tumorigenic activity of ERBB4 in breast cancer
[16,17]. As very different biological activities are induced
in tissue culture by CYT-1 and CYT-2 isoforms, and as
only JM-a ERBB4 can be cleaved to yield the nuclear
form, it is possible that the impact of ERBB4 varies con-
siderably depending on isoform or cleavage. In vitro, the
ICD of ERBB4 suppresses proliferation and induces differ-
entiation, but, interestingly, ribozyme-mediated ERBB4
downregulation and use of antibody against cleavable
ERBB4 has also been shown to suppress tumor cell prolif-
eration [18-20]. In one breast cancer study, high expression
of ERBB4 was associated with a favorable outcome in es-
trogen receptor-positive cases; in the same study, nuclear
ERBB4 immunoreactivity was associated with poor survival
as compared with women whose cancer had membranous
ERBB4 staining [21]. Nuclear ERBB4 ICD is inversely cor-
related with tumor grade and tumor mitosis, while cyto-
solic ERBB4 ICD has significant positive prognostic value
in lymph node-negative breast cancer patients [22].
In tissue culture, JM-a CYT-1 and CYT-2 ERBB4 iso-
forms exhibit a range of cellular functions depending on
the cell type and the receptor model system studied; that
is, whether full length (FL) or artificially truncated (ICD)
receptors are investigated. The CYT-1 isoform has anti-
proliferative activity in SUM102 mammary cancer cells,
32D bone marrow cells, and HC11 and MCF10A mam-
mary epithelial cells, while CYT-1 ERBB4 promotes
tumorigenesis in ovarian OVCAR-3 and SKOV-3 cancer
cell lines [23-27]. In mice, expression of sequences en-
coding the s80 CYT-1 ICD decreased mammary ductal
growth with no effect on lobuloalveolar growth whereas
CYT-2 caused mammary epithelial hyperplasia [23].
While this study was important in revealing major differ-
ences between CYT-1 and CYT-2 isoforms in the mouse
mammary gland, these observations were made with a
Wali et al. Breast Cancer Research  (2014) 16:501 Page 3 of 15constitutively active truncated ErbB4 that in tissue cul-
ture has greater signaling power and possibly different
signaling targets from the FL molecule [25]. In vivo, the
signaling activity of ErbB4 isoforms will be a composite
of intact ErbB4 signaling, through recruitment of signal-
ing proteins to noncleaved ERBB4 embedded in cellular
membranes, and through the very different signaling
qualities associated with constitutively active soluble
ERBB4, much of which homes to the nucleus. Moreover,
the biological activities will be modulated by endogenous
activation of metalloproteinases and γ-secretase activ-
ities. To address the in vivo signaling properties of intact
ErbB4 isoforms expressed in transgenic animals, we pro-
duced a gain-of-function transgenic mouse model that
overexpresses FL CYT-1 and CYT-2 JM-a ERBB4 human
transgenes driven by the mouse mammary tumor virus
(MMTV) promoter/enhancer sequences, in order to
evaluate the potential developmental and carcinogenic
roles of ERBB4 CYT-1 and CYT-2. This model system
was used to address uncertainties about the role of each
FL ERBB4 isoform in nulliparous and parous mammary




Plasmids encoding human ERBB4 isoforms JM-a CYT-1
ERBB4 and JM-a CYT-2 ERBB4, under control of the
MMTV long terminal repeat, the vRAS 5′-untranslated
region, human ERBB4 cDNAs, and the SV40 polyadenyla-
tion site were produced by ligating the insert fragments
ERBB4 JM-a CYT-1 and ERBB4 JM-a CYT-2 from
pcDNA3.1 into digested pMMTV-erbB4ΔIC as vector.
Briefly, pMMTV-erbB4ΔIC was digested with EcoRI,
blunted using T4 polymerase and digested again with
BstEII, and the resulting 8,300 base pair vector fragment
was isolated from an agarose gel and spin-column
purified. pcDNA3.1.ERBB4JM-aCYT-1 and pcDNA3.1.
ERBB4JM-aCYT-2 were digested with BstEII and PmeI,
and the resulting JM-a CYT-1 and JM-a CYT-2 fragments
were isolated from an agarose gel, spin-column purified,
and ligated into digested pMMTV. Inserts from the final
constructs were confirmed by DNA sequencing. The
insert separated by SalI-AatII digestion was gel purified
(Figure 1A) and micro-injected into fertilized ova from
FVB females, which were implanted into pseudopreg-
nant CD1 female mice by the Yale Animal Genomics
Services core (New Haven, CT, USA). DNA from tail
biopsies of offspring was genotyped for ERBB4 using PCR
primers 5′-CTGGTCATTGTGGGTCTGAC, correspond-
ing to nucleotides 2,088 to 2,107 of exon 17, and 5′-CTC
CTTCCAAGAGTCTGGCT, the reverse complement
corresponding to nucleotides 2,690 to 2,709 of exon 21 of
ERBB4. Transgene-positive mice were backcrossed withFVB mice and their progeny were tested for transmission
of the transgene. Multiple lines were found to express the
transgene. In this study, lines L2 for CYT-1, and V12 for
CYT-2 were used for detailed analysis. The transgenes
were inherited according to Mendelian expectations for
heterozygotes. All animal work was approved by Yale Uni-
versity Institutional Animal Care and Use Committee and
followed internationally recognized guidelines.
RNA extraction and ERBB4 transgene expression
Mammary tissue from transgenic mice and sibling controls
was isolated at various developmental stages, and stored im-
mediately in RNAlater (Qiagen; Valencia, CA, USA). The tis-
sue was homogenized and total RNA was isolated with the
RNeasy Plus Mini Kit (Qiagen) and reverse-transcribed with
the iScript cDNA Synthesis Kit (BioRad; Hercules, CA,
USA), using 1 μg RNA per reaction. Universal TaqMan
Master Mix (Applied Biosystems; Grand Island, NY, USA)
was used for real-time quantitative reverse transcription
PCR analysis of a 1:10 dilution of the resulting cDNA.
ERBB4 transgene mRNA expression was quantified by real-
time quantitative reverse transcription PCR using Taqman
primers (Applied Biosystems) for ERBB4 (Hs00171783_m1)
and mouse-specific beta-2 microglobulin (Mm03003532_u1)
according to the manufacturer’s protocols. Relative mRNA
expression was determined with the ΔCt method, with
mouse-specific beta-2 microglobulin as the reference gene.
The ERBB4 antibody (sc-283) used for immunohisto-
chemistry (IHC) binds to the intracellular region near the
carboxyl terminus of ERBB4, and reacts with both mouse
and human ERBB4.
Whole mount staining and terminal end bud count
Left-side #4 mammary glands were isolated from female
mice for whole mount staining with Carmine Alum. Briefly,
mammary glands were air dried for 10 to 15 minutes on a
clean glass slide, and fixed in Carnoy’s fixative (75%
ethanol + 25% acetic acid). Slides were then washed in
70% ethanol, rinsed in water, and stained overnight with
Carmine Alum, followed by sequential dehydration steps
in 70%, 95% and 100% ethanol. Afterward, glands were
defatted in acetone, cleared in xylene and mounted with
Permount and coverslipped. Terminal end buds (TEBs) in
the Carmine Alum-stained mammary whole mount slides
were counted manually under magnification.
Quantification of mammary ductal morphogenesis
Entire glands were photographed under a dissection micro-
scope with a SPOT 11.2 Color Mosaic camera (Diagnostic
Instruments Inc; Sterling Heights, MI, USA) at 10× magnifi-
cation using SPOT advanced software 4.0.9 (Diagnostic
Instruments Inc; Sterling Heights, MI, USA) (Figures S1 to
S8 in Additional file 1). Images were analyzed and quantified
with ImageJ software (Wayne Rasband, National Institutes
Figure 1 ERBB4 transgene expression. (A) Plasmid map for MMTV-ERBB4 carrying SalI and AatII sites. SalI-AatII double digestion of the plasmid
separated the ERBB4 CYT-1(A1) and CYT-2 (A2) inserts, which were gel purified for micro-injections to generate CYT-1 and CYT-2 ERBB4 transgenic
mice. (B) ERBB4 mRNA expression in the mammary glands of CYT-1 and CYT-2 mice at various developmental stages. RNA was extracted from
mammary glands from three mice at each stage and pooled. Relative ERBB4 expression levels are represented by vertical bars as measured by
real-time quantitative reverse transcription PCR using Taqman primers, with error bars indicating the standard deviation for samples run in triplicate.
(C) ERBB4 immunohistochemical staining (detecting both mouse endogenous and human transgenic ERBB4) in nonpregnant multiparous female
transgenic and control FVB mice. β2m, mouse-specific beta-2 microglobulin; MMTV, mouse mammary tumor virus.
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calculated as the percentage of the distance from the lymph
node to the farthest point of the longest duct relative to the
distance to the farthest limit of the mammary fat pad.
For measuring ductal branching in virgin mice, branch
points were counted manually in three random unitareas using ImageJ software. At each developmental
stage, between three and 12 mice were quantified in
both sibling control and transgenic groups. Statistical
analysis was performed using one-way analysis of variance
using Newman–Keuls post-analysis of variance multivari-
ate analysis. Post-coitus whole mount mammary glands
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highest to lowest branching density after microscopic
inspection.
High-resolution individual and composite digital light
microscopic representative images of developing mammary
glands at 5, 8, and 14 weeks from control, CYT-1 and CYT-
2 mice were recorded using an Axio Imager.A.1 microscope
with an AxioCam MRc5 camera and AxioVision 4.7
imaging software (Zeiss; Thornwood, NJ, USA). Images
were optimized in Adobe Photoshop CS5 12.0.4 (Adobe
Systems Inc.; San Jose, CA, USA).Evaluation of mammary tumor lesions
Mammary lesions were identified by gross examination
of mammary glands and stained by carmine alum in the
whole mount slides. These mammary glands were paraf-
fin embedded and thin sections were stained with
hematoxylin and eosin (H&E). Microscopic pathological
examination of these H&E slides was performed and the
lesions were categorized according to their histological
characteristics (Additional file 2).Hematoxylin and eosin, Masson trichrome stain and
immunohistochemistry
A portion of the right #4 inguinal mammary gland was
spread onto a glass microscope slide and fixed in freshly
prepared 4% paraformaldehyde in phosphate-buffered
saline overnight. The fixed tissue was embedded in par-
affin, and 5 μm sections were dried onto gelatin-coated
slides. Samples were then deparaffinized and rehydrated
in distilled water. Endogenous peroxidase was quenched
with hydrogen peroxide. Masson trichrome and H&E
staining were performed according to standard methods.
Primary antibodies ErbB4 and Stat5a (Santa Cruz
Biotechnology; Dallas, Texas, USA), p63, CK5/6 and
proliferating cell nuclear antigen (PCNA; Dako, Carpin-
teria, CA, USA), Vimentin, E-cadherin and smooth
muscle actin (Thermo Scientific, Waltham, MA, USA),
and Ki-67 (Biocare Medical, Concord, CA, USA) were
used for immunohistochemistry on formalin-fixed
paraffin-embedded sections. Immunoreactivity was de-
tected with the peroxidase-based Envision + system
(Dako). Diaminobenzidine was used to detect the antibody
complex (Dako). The slides were subsequently counter-
stained with hematoxylin and then dehydrated and perman-
ently coverslipped in resin mounting media. For PCNA
quantification in TEBs, the total number of TEBs (positive
and negative for PCNA) per section (n = 4 for each control
and transgenic mice) was counted under the microscope;
within each TEB positive for PCNA, the percentage of
PCNA-positive cells was calculated by counting PCNA-
positive versus all luminal TEB cells.Results
ERBB4 expression during development
To compare biological activities of ERBB4 CYT-1 and
CYT-2, we produced transgenic mice in which human
ERBB4 cDNAs are expressed under control of the
MMTV promoter/enhancer (Figure 1A). Since the gen-
omic integration site affects the expression levels of
transgenes driven by the MMTV promoter, ERBB4 ex-
pression in mammary glands was assessed in multiple
mice lines by real-time quantitative reverse transcription
PCR, and lines with higher expression (L1 in CYT-1
group and V12 in CYT-2) in virgin mice were used for
further analysis. ERBB4 expression was detected by real-
time quantitative reverse transcription PCR in virgin,
post-coitus and post-partum female transgenic mice
(Figure 1B). In FVB mice, MMTV-driven transgenes are
expressed mainly in the mammary epithelium, and usu-
ally at low levels in young animals, with higher expres-
sion in pregnancy and lactation. As expected, expression
of ERBB4 CYT-1 and CYT-2 transgenes was significantly
higher in pregnant (12 days post coitus) and lactating
mice and 1-day post-partum females compared with pu-
bescent 5-week-old mice. Similar expression trends
across developmental stages were seen in both CYT-1
and CYT-2 transgenic mice; direct comparison between
mice harboring the two transgenes at each stage revealed
comparable expression levels. ERBB4 was not detectable
by IHC in virgin mice, but ErbB4 was readily detected by
IHC in multiparous nonpregnant female mice (Figure 1C).
Staining intensity and number of ERBB4 positively stained
cells was clearly higher in transgenic mice mammary glands
as compared with background FVB mice (Figure 1C).
Transgenic ERBB4 expression effect on mammary gland
development
EGFR, ErbB2, and ErbB3 are required for normal mouse
mammary development at puberty, but ErbB4 has mainly
been implicated in pregnancy and in lactation [4,28-32]. At
5 weeks of age, no differences were evident between mam-
mary ducts of control and ERBB4 transgenic female mice,
which traverse approximately 25 to 30% of the fat pad by
this time. However, at 8 weeks, mammary ductal growth
and branching of ERBB4 CYT-1 mice was significantly
lower than that of sibling controls as well as that of ERBB4
CYT-2 mice, with approximately 60% average ductal pene-
tration of the fat pad in CYT-1 mice as compared with
~80% growth in other groups (Figures 2A,B,C and 3A).
Moreover, ductal branching density of ERBB4 CYT-1
mice (approximately 20 branches per unit area) was ap-
proximately one-half that of sibling controls (approxi-
mately 40 branches per unit area) (Figures 2B and 3A).
Although mammary ductal growth of CYT-2 mice was
not significantly different from sibling controls, CYT-2
mammary ductal branching was significantly decreased at
Figure 2 (See legend on next page.)
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Figure 2 Quantitative analysis of mammary ductal elongation and branching. Mammary gland #4 was isolated from 5-week-old, 8-week-old
and 14-week-old (5w, 8w and 14w) CYT-1 (red circle) and CYT-2 (red triangle) ERBB4 transgenic mice and their respective transgene negative sibling
controls (blue circles and triangles), and was processed for whole mount analysis using Carmine Alum stain. (A) Stained whole mounts were
photographed under a dissection microscope with a SPOT 11.2 Color Mosaic camera at 10× magnification using SPOT advanced software 4.0.9 (Diagnostic
Instruments Inc; Sterling Heights, MI, USA). Ductal growth and branching were measured using ImageJ software (National Institute of Health, Bethesda,
Maryland, USA). (B) For ductal branching, branch points were counted manually in three random unit areas using ImageJ software and averaged for each
mouse. Data points indicate branch points ± standard error of the mean (SEM) in each group. (C) Ductal elongation/growth was calculated as the
percentage of the distance from the lymph node to the farthest point of the longest duct relative to the distance to the farthest limit of the mammary
fat pad. Data points indicate percent growth ± SEM in each group. ***P <0.001, **P <0.01, *P <0.05 by one-way analysis of variance (ANOVA) using
Newman–Keuls post-ANOVA multivariate analysis.
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age, mammary ducts in all of the groups nearly filled the
mammary fat pad (100% ductal growth). Ductal branching
in 14-week-old CYT-2 mice was at or near the levels of sib-
ling controls, but branching in CYT-1 mice remained sig-
nificantly lower than the controls (Figures 2B and 3A).
TEBs were evident in whole mounts of 5-week and 8-week
mammary glands, but had regressed by 14 weeks
(Figure 3A). There was no significant difference between 5-
week control and transgenic groups, but a significantly
lower number of TEBs (average ~18) was found in CYT-1
whole mount mammary gland slides as compared withFigure 3 Quantification of terminal end buds and proliferating cell nu
microscopic representative images of developing mammary glands at 5, 8, an
Axio Imager.A.1 microscope with an AxioCam MRc5 camera and AxioVision 4
the gland area, arrowheads point to the end of the terminal end buds (TEBs).
gland whole mount slides was counted manually under magnification in tran
<0.0001 by one-way analysis of variance (ANOVA) using Tukey’s post-ANOVA
TEBs (TEBs with at least one luminal cell displaying positive PCNA nuclear stain
8-week-old CYT-1 mice and sibling controls were counted, and expressed as p
calculated for each PCNA-positive TEB within a section of 8-week mamm
*P <0.05 by unpaired t test. (E) Representative hematoxylin and eosin (HE
Scale bars = 50 μm.control (average ~61) (Figure 3B). Immunostaining of
PCNA in thin sections revealed a large variation in the per-
centage of TEBs with PCNA-positive nuclei as compared
with the CYT-1 group, but these differences were not
statistically significant (Figure 3C). Within each PCNA-
positive TEB (with at least one cell with positive PCNA
nuclear staining), the percentage of PCNA-positive cells
was lower in the CYT-1 group (Figure 3D,E). Decreased
mammary ductal growth and branching in 8-week-old
CYT-1 mice was thus associated with decreased proliferat-
ing cells within the TEBs. H&E staining of TEBs of
8-week-old CYT-1 mice also suggested a possible defect inclear antigen staining. (A) High-resolution composite digital light
d 14 weeks from control, CYT-1 and CYT-2 mice were recorded using an
.7 imaging software (Zeiss, Thornwood, NJ, USA). LN, lymph node. *End of
Scale bars = 1,000 μm. (B) The number of TEBs in 8-week-old mammary
sgenic CYT-1 and CYT-2 mice and their respective sibling controls. ****P
multivariate analysis. (C) Proliferating cell nuclear antigen (PCNA)-positive
ing) and total number of TEBs in thin mammary tissue sections of
ercent positive for PCNA. (D) Percent PCNA-positive cells were
ary gland in four mice in each control and CYT-1 and were averaged.
) and PCNA stained images of TEBs in 8-week mammary glands.
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ent decrease in body cell number and larger luminal
spaces compared with controls (Figure 3E).
In pregnant mice 12 days post coitus, mammary
gland ductal branching continued to be less dense in
CYT-1 transgenic mice than for CYT-2 or control ani-
mals (Figure 4A,B,C). This was confirmed with H&E
staining, which additionally indicated underdeveloped
milk glands in CYT-1 mice, as controls had larger
number of large acini and more flattened epithelial cells
(Figure 4D). However, at 19 days post coitus, 1 day post
partum, 16 days post partum, and 16 days post wean-
ing, mammary whole mounts and H&E histology of
thin sections revealed no major differences in mam-
mary gland morphology among control and transgenicFigure 4 Mammary ductal branching density in post-coitus mice. (A)
of 12-days post-coitus (12d PC) and 1 day post-partum (1d PP) control, CYT-1, a
an AxioCam MRc5 camera and AxioVision 4.7 imaging software (Zeiss, Thornwo
Instruments Inc; Sterling Heights, MI, USA) for a magnified image. (C) 12d PC who
for highest to lowest branching density after microscopic inspection. Data points
unpaired t test. (D) Representative hematoxylin and eosin (HE) image of contrgroups (Figures S1 to S8 in Additional file 1). Interestingly,
multiparous CYT-1 mammary glands appear morpho-
logically distinct from the FVB control and CYT-2 mam-
mary glands with, fewer lobuloalveolar structures. This is
consistent with a growth inhibitory role of CYT-1 ERBB4
during early developmental stages.
Tumorigenesis in ERBB4 transgenic mice
The role of ERBB4 in breast cancer is uncertain. To pro-
mote chronic ERBB4 signaling through overexpression with
maximal activity of the MMTV promoter, we maintained
12 CYT-1 females and 12 CYT-2 females in continuous
breeding with nontransgenic control males. Six control fe-
male FVB mice were continuously bred separately. At the
end of approximately 1 year (52 weeks), these multiparousHigh-resolution composite digital light microscopic representative images
nd CYT-2 mice were recorded using an Axio Imager.A.1 microscope with
od, NJ, USA), or (B) a SPOT 11.2 Color Mosaic camera (Diagnostic
le mount mammary glands were blinded and scored over a range of 1 to 10
indicate percent growth± standard deviation in each group *P <0.05 by
ol and CYT-1 PC-12 mammary gland thin section. Scale bars = 50 μm.
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gland whole mounts revealed single or multiple tumor le-
sions in 10 out of 12 CYT-1 mice (Figure 5A). Two out of
12 of the CYT-2 group showed hyperplastic regions, whereas
no significant findings were observed in the control group
(0/6). One mouse in the CYT-1 group also developed a
2.0 cm× 2.0 cm solid mammary tumor (Figure 5B) in
addition to multiple smaller mammary lesions. The MMTV
promoter has been used extensively in mammary tumor
mouse models to study the phenotypes of transgenes in the
FVB mouse background. These include wild-type neu/ErbB2
transgenic mice with tumor latency of 30 to 52 weeks, and
MMTV-cyclin D1 mice with approximately 70 weeks as
mean age at onset [33,34]. Spontaneous mammary hyperpla-
sia and tumor incidence have been reported in multiparous
female FVB mice, but with a latency period >80 weeks [35].Figure 5 Mammary tumorigenesis in mouse mammary tumor virus C
52-week-old multiparous CYT-1 ERBB4 transgenic mice. (A) Low-magnific
low-magnification (middle) and high-magnification (bottom) bright-field
(B) Low-magnification bright-field image before whole mount analysis of
separated from the same mouse (right). Scale bar = 1 cm.Lesions were first identified by visual inspection while
isolating mammary glands, and they were conspicuous in
carmine alum-stained whole mounts. Paraffin-embedded
thin sections stained with H&E were evaluated microscop-
ically. Pathological examination of these H&E slides charac-
terized these identified lesions as neoplastic or hyperplastic
(Additional file 2).
Characteristics of tumor lesions
Histopathological examination of H&E-stained and immu-
nostained slides showed that tumor lesions from ERBB4
CYT1 mice showed similar characteristics, with regions of
hyperplasia or carcinoma with glandular or squamous dif-
ferentiation or solid tumor (Figure 6; Additional file 2).
Non-neoplastic mammary gland regions in transgenic
mice were structurally similar to those of nontransgenicYT-1 ERBB4 transgenic mice. Mammary tumor lesions observed in
ation bright-field image (top) before whole mount analysis, and
image after whole mount analysis in the same female CYT-1 mouse.









Figure 6 (See legend on next page.)
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Figure 6 Immunohistochemical analysis of mammary tissue in serial sections. Immunohistochemistry images of the mammary tissue
isolated from age-matched (52-week) female multiparous control FVB (normal) mice, and abnormal regions observed in CYT-2 (hyperplasia) and
CYT-1 (adenocarcinoma, squamous differentiation, solid tumor) ERBB4 transgenic mice. Stained representative images of the mouse mammary
tissue obtained from FVB control (n = 3), CYT-2 with hyperplastic region (n = 1) and CYT-1 (n = 3) carcinoma, and a single 2 cm × 2 cm CYT-1 solid
tumor. Tissues were embedded in paraffin sections and stained for hematoxylin and eosin (HE), Masson trichrome (MTC; stains for collagen (blue),
nuclei (black) and muscle/keratin (red)), ErbB4, cell proliferation marker Ki-67, signal transducer and activator of transcription 5a (STAT5a), smooth
muscle actin (SMA; stains for smooth muscle and myoepithelium), epithelial markers E-Cadherin (E-Cad) and cytokeratin 5/6 (CK5/6), and mesenchymal
markers Vimentin (Vim) and p63. Scale bars = 50 μm.
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gests a common underlying cause for neoplastic trans-
formation in CYT-1 mice. Interestingly, the hyperplastic
regions observed in two CYT-2 mice were very similar to
those seen in all CYT-1 mammary lesions, suggesting a
qualitative overlap in the tumorigenic processes between
CYT-1 and CYT-2 ERBB4 transgenic mice. Although hy-
perplastic regions in CYT-2 mice qualitatively appear to
be a subset of the CYT-1 phenotype, they occurred with
low incidence (only 2/12) and so are difficult to compare
quantitatively with the more penetrant CYT-1 lesions
(10/12). Gross examination of tissue did not reveal
overt signs of metastatic lesions in the liver, lungs, kidneys,
or brain. Morphologically, MMTV-CYT-1 adenocarcin-
omas do not resemble MMTV-Neu and MMTV-PyVmT
tumors. CYT-1 also differs from these tumors in latency
period (4 months, MMTV-Neu; 5 weeks, MMTV-PyVmT)
and because no tumors develop in virgin CYT-1 mice in
contrast to the other two tumor models. Although there is
expansion of the basal compartment in CYT-1 adenocar-
cinoma, the single large tumor observed is more similar to
these models. However, CYT-1 tumors somewhat resem-
ble slow-growing MMTV-cyclin D1 tumors (with latency
of approximately 500 days), which are characterized by
squamous differentiation as seen in CYT-1 [33,34].
Breast carcinomas express ERBB4 that correlates with
STAT5a and Ki-67 staining
ERBB4 protein was stained by IHC with an antibody that
reacts with both mouse and human ERBB4. IHC of mam-
mary tissues showed that ErbB4 levels were higher in
transgenic mice as compared with nontransgenic mice
(Figure 1C). Figure 6 shows the histopathology of mam-
mary tissue derived from normal (nontransgenic) mice, hy-
perplastic (CYT-2) mice, and carcinoma with glandular and
squamous cell differentiation (CYT-1 mice). These micro-
scopic images are representative of multiple thin sections
obtained from three FVB control mice, three CYT-1 mice
(carcinoma), and one CYT-2 mouse with a hyperplastic re-
gion. One mouse had a solid mammary carcinoma lacking
both glandular and squamous cell differentiation (CYT-1
mouse). Within the transgenic mammary tissue, ERBB4
cytoplasmic staining was observed (50 to 100%) in CYT-1
glandular cells and in squamous tumor epithelial cells withscattered positive cytoplasm (~25 to 50%), while mesenchy-
mal cells displayed little or no staining for ERBB4 (Figure 6).
Solid tumor areas (CYT-1) contained neoplastic cells with-
out any mammary ductal architecture, had necrotic regions,
and displayed many scattered ERBB4 stained cells across
the section. It is noteworthy that regions of ERBB4 expres-
sion contained highly proliferating cells, indicated by strong
positive Ki-67 labeling (Figure 6). Furthermore, glandular
carcinoma cells with higher percentage of ERBB4 also
stained for STAT5a (50 to 100%) while tumor cells with
squamous cell differentiation, and skeletal and smooth
muscle cells stained negative for STAT5a. ErbB4 is known
to bind and activate STAT5a and also increase its transcrip-
tional activity [36]. To test whether ERBB4 induces epi-
thelial–mesenchymal transition in mammary cells, we
evaluated mesenchymal and epithelial markers. We found
no evidence of epithelial–mesenchymal transition, as the
protein expression patterns between luminal and myoe-
pithelial cells were well demarcated by positive epithelial
cell staining for E-cadherin while myoepithelial cells (mes-
enchymal) stained positive for vimentin, smooth muscle
actin and CK5/6. Interestingly, mesenchymal cells within
glandular carcinoma in CYT-1 mice showed very low p63
labeling, unlike other mesenchymal markers. CYT-1 glan-
dular carcinoma cells expressing ERBB4, and STAT5a, and
displaying Ki-67 staining, suggest a pro-proliferative role
of ErbB4 in these tumor lesions. A recent study demon-
strated that the ERBB3/ERBB4 ligand NRG1 is directly
transcriptionally regulated by p63 expressed in myoe-
pithelial cells, which induces luminal progenitor cell
proliferation and milk production via paracrine ErbB4/
STAT5a activation in luminal epithelium [37]. Since we
found that p63 expression in CYT-1 expressing lesions
is suppressed, this suggests a converse paracrine relation
or feedback regulation between luminal epithelial
ERBB4 and basal p63, wherein overexpression of CYT-1
isoform may be suppressing p63 expression. Masson tri-
chrome stained collagen around ducts, keratin and
muscle fibers present in connective tissue and nuclei.
Synaptophysin, a marker for tumors of neuronal origin,
was used as a negative control and, as expected, was
negative in tumor tissue. F480, a macrophage marker,
stained scattered macrophages in tumor lesions as
expected (Additional file 3).
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We developed transgenic mouse models overexpressing
JM-a FL ERBB4 isoforms in mammary glands to deter-
mine the role of each isoform in mammary development
and carcinogenesis. The FL CYT-1 isoform suppressed
both mammary ductal elongation and branching in pu-
bescent mice, with a concomitant reduction in the num-
ber of TEBs and the percentage of proliferating luminal
cells in TEBs. FL CYT-2 isoform also mildly suppressed
branching but did not affect ductal elongation in pubes-
cent animals. The suppressive effect of CYT-1 expres-
sion on ductal branching was maintained in pregnant
mice until mid-pregnancy, after which ERBB4 transgenic
mice were developmentally similar and indistinguishable
from controls. Finally, sustained expression of FL CYT-1
induced ERBB4-positive mammary tumor lesions in
nearly all of the CYT-1 mice, indicating a tumorigenic
function of this ERBB4 isoform in mammary epithelium.
Postnatal development of the mammary gland involves
ductal and secretory phases that are regulated by con-
certed interplay of systemic hormones, locally secreted
growth factors, and their receptors – including the
EGFR family, which plays a major role [38,39]. EGFR
family members EGFR and ErbB2 are expressed abun-
dantly and are active at all developmental stages, while
ErbB3 and ErbB4 are mostly active during pregnancy
and lactation. In the present study, the expression of
ErbB4 isoforms was highest in pregnant and lactating
mice. However, in pubescent mice – when ErbB4 expres-
sion is normally much lower – CYT-1 ERBB4 transgene
expression in mammary epithelium suppressed both
mammary ductal elongation and branching, whereas the
CYT-2 isoform had a suppressive effect on branching. The
CYT-1 pubescent phenotype extended towards mid-
pregnancy as CYT-1 isoform expression resulted in less
dense mammary branching architecture until 12 days post
coitus. We observed previously that mammary gland de-
velopment of pubescent ErbB4 knockout mice outpaced
the growth of sibling controls, which is consistent with a
suppressive effect of ErbB4 [5]. However, this CYT-1
ERBB4 phenotype is in sharp contrast with the functions
of EGFR, ErbB2, and ErbB3, which promote mammary
ductal morphogenesis in pubescent mice [29]. Loss of
function of either ErbB4, prolactin, prolactin receptor,
JAK2, or STAT5 by various genetic methods results in simi-
lar phenotypes in mice characterized by impaired pregnant
mammary lobuloalveolar growth and lactation defects
[4,40-42]. Impaired processing of ERBB4 ligand heparin-
binding epidermal growth factor-like growth factor also
impairs lactation [43]. Collectively, these data suggest
that the branching and especially elongation pheno-
types are mediated predominantly through EGFR,
ErbB2, and ErbB3, when ErbB4 may play a minor
suppressive function, whereas the pro-differentiationphenotypes manifested late in pregnancy and during
lactation are mediated through ErbB4.
Suppressed ductal morphogenesis by CYT-1 ERBB4
may result from the smaller number of proliferating cells
observed within the CYT-1 TEBs. This effect on cell
proliferation could be mediated through both cellular
and tissue-level effects of ERBB4 signaling. In vitro, the
transforming growth factor-beta pathway has been
shown to be upregulated by ErbB4 activation in T47D
and MCF10A mammary carcinoma cells [25,44]; in vivo,
epithelial transforming growth factor-beta inhibits for-
ward movement of TEBs [45]. Although activated
ERBB4 has been shown to induce apoptosis [46], we
found no evidence of apoptosis, as indicated by the ab-
sence of cleaved caspase-3 immunoreactivity (data not
shown). The unique activities of ErbB4 are mediated
partly through activities of cleaved nuclear isoforms that
affect transcription through binding to Stat5, YAP, and
other transcriptional regulators [25,47]. Also, luminal
cells were loosely packed in 8-week MMTV-CYT-1
TEBs. This may be relevant to the phenotype, as disrup-
tion of cell–cell contacts within TEBs inhibits cell prolif-
eration and ductal growth [48].
GFP-tagged ICD CYT-1 and CYT-2 have been
expressed in mouse mammary glands using a doxy-
cycline-inducible transgenic model [23], in which
CYT-2 increased while CYT-1 decreased pubertal
growth of mammary ducts. CYT-1 mice had fewer
TEBs with lower proliferative index, while CYT-2
mice had more TEBs with higher fraction of prolifer-
ating cells. While biologically interesting, this mouse
model does not fully recapitulate the physiological ac-
tivity of FL ERBB4. Unlike cleaved ICDs that are con-
stitutively active and equally capable of entering the
nucleus, FL ERBB4 must undergo a two-step cleavage
event at the membrane to generate cytoplasmic and
nuclear pools of ERBB4. Our FL mouse model ex-
pressing FL ERBB4 brings in this additional level of
regulation by endogenous agonists and metallopro-
teinases at physiologically relevant levels. Comparing
our FL model with the previously described ICD
model allows us to speculate on the relative contribu-
tion of ERBB4 at the membrane. Both FL ERBB4 CYT-
1 mice and CYT-1 ICD mice showed similar phenotypes
of suppressed ductal elongation with decreased numbers
of TEBs and proliferating cells, but ICD CYT-1 did not
suppress ductal branching in pubertal or pregnant mice.
In contrast with FL CYT-2, which had no effect on TEBs
and a slight suppressive effect on branching, ICD CYT-2
mice showed an increase in TEBs and cellular proliferation
and hyperplasia. These observations suggest that CYT-1
ICD mirrors FL CYT-1 function more so than CYT-2 ICD
recapitulates FL CYT-2 during mammary development.
The major difference between FL and ICD ERBB4
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ductal branching, only seen with FL ERBB4 isoforms,
which may be due to membrane-associated functions of
FL ERBB4.
Overexpression of ErbB1, ErbB2, and ErbB3 in trans-
genic mouse models contributes to mammary tumor for-
mation. Mammary gland-specific human EGFR transgene
expression under MMTV long terminal repeat induces
neoplasia in mice [49]. Similarly, elevated expression of ac-
tivated forms of Neu/ErbB-2 and ErbB3 are involved in
the induction of mammary tumors in MMTV-Neu trans-
genic mice [50]. In contrast, transgenic expression of trun-
cated ERBB4 isoforms did not induce neoplasia [23].
But sustained expression of the FL CYT-1 ERBB4 iso-
form resulted in the formation of neoplastic lesions/
tumor in the present study, while CYT-2 expression
only caused a low incidence of hyperplasia, hinting at a
possible milder oncogenic predisposition of CYT-2.
CYT-1 ERBB4-induced tumors may develop either dir-
ectly by sustained and enhanced downstream ERBB4
signaling in a FVB genetic background, or from ERBB4
signaling acting in concert with secondary genetic or
epigenetic alterations acquired over a 1-year period.
Nonetheless, the similar tumor characteristics in all
CYT-1 mice suggest the former rather than the latter.
Multiparous transgenic female mice expressing NRG1,
a ligand for ERBB3 and ERBB4, under control of the
MMTV promoter also develop adenocarcinomas in the
mammary glands at a median age of 12 months [51],
suggesting ErbB4 to be contributing to neuregulin-
induced carcinogenesis. In the composite ErbB signaling
network, whether overexpressed CYT-1 induces expres-
sion of agonists such as neuregulins and/or interacts with
ERBB3 and ERBB2 more efficiently, enabling it to be
tumorigenic, awaits further investigation. Notably, it was
recently shown that expression of CYT-1 ERBB4 is associ-
ated with poor survival from ovarian cancer [24]. Analysis
of mammary gland mRNA expression of the CYT-1 and
CYT-2 isoforms also indicates a higher ratio of CYT-1:
CYT-2 expression in breast cancers (>50% CYT-1) versus
normal mammary glands (<40% CYT-1) [1]. Expression of
FL ERBB4 probably creates more complex phenotypes
arising from the dynamic state of the receptor (membran-
ous, nuclear, or cytoplasmic), extracellular interactions,
and a milieu of endogenous agonists that are differentially
expressed (NRG1, heparin-binding epidermal growth
factor-like growth factor, betacellulin, and so forth) that
probably contribute to the phenotypes we observed.
Conclusions
These ERBB4 mouse models are the first to describe
overexpression of ERBB4 in noncardiac tissue. They are
especially significant as ERBB4 overexpression is more
frequent than ERBB4 mutations in cancer, but thebiological impact is uncertain. The mammary pheno-
types resulting from FL ERBB4 expression most closely
model complex ERBB4 functions resulting from com-
posite signaling by intact and truncated (s80) ERBB4.
Results of the present study demonstrate different func-
tional roles of ERBB4 isoforms in mammary development,
and mammary tumorigenesis. ERBB4 CYT-1 initially sup-
presses mammary ductal morphogenesis, but eventually
this defect is corrected later in development. We describe a
causal relation between CYT-1 ERBB4 expression and
tumorigenesis in transgenic mice. Together, these results
significantly expand the understanding of ErbB4 function
in early developmental phases when its expression is low,
and reveal novel oncogenic properties of ERBB4 CYT-1
isoform. These findings also suggest that it might be ad-
vantageous to inhibit ERBB4 specifically or use pan-ERBB
inhibitors for treatment of certain subsets of breast cancer.
Additional files
Additional file 1: Figures S1 to S8 showing left-side #4 mammary
glands isolated from female transgenic and sibling FVB control mice for
whole mount staining with Carmine Alum: 5 weeks virgin (Figure S1),
8 weeks virgin (Figure S2), 14 weeks virgin (Figure S3), 12 days post-
coitus CYT-1 (Figure S4), 12 days post-coitus CYT-2 (Figure S5), 19 days
post-coitus (Figure S6), 1 day post-partum (Figure S7), and 16 days
post-weaning (Figure S8). Entire glands were photographed under a
dissection microscope with a SPOT 11.2 Color Mosaic camera (Diagnostic
Instruments Inc.) at 10× magnification using SPOT advanced software 4.0.9,
and analyzed.
Additional file 2: Figure S9 showing whole mounts of mammary
glands from nonpregnant age-matched (52-week) multiparous
female control, CYT-1 and CYT-2 mice removed from glass slides,
embedded in paraffin sections and stained by H&E by routine
methods for verification of pathologic findings compared with
control (A) mice. CYT-1 mice mammary glands had the following
pathologic changes: mild glandular hyperplasia (B), moderate
glandular hyperplasia (C), or neoplasia (D to N). Neoplasia varied
from single small adenomas within hyperplasic regions, diffuse areas with
ductular hyperplasia (E) to discrete adenocarcinomas (F to N) of which
many had foci of squamous differentiation (G, K, M, N) and frequent
inflammatory cells (H, K, L, N). Two out of 12 CYT-2 mice (O to Q) also
had lesions but fewer than CYT-1 mice, and pathologic changes were
similar: glandular hyperplasia (O), adenocarcinoma (P), and squamous
differentiation (Q). Scale bars = 50 μm.
Additional file 3: Figure S10 showing mammary tissue isolated
from age-matched (52-week) female multiparous control FVB
(normal), abnormal regions observed in CYT-2 (hyperplasia), and
CYT-1 (adenocarcinoma, squamous differentiation, solid tumor) ERBB4
transgenic mice, embedded in paraffin sections and processed for
immunohistochemistry to stain for synaptophysin (Synap), a marker for
tissues of neuronal origin, and F/480 (F480), which stains macrophages.
Scale bars = 50 μm.
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